| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $17.5M | -75.2% |
| SG&A Expense | $16.7M | -36.1% |
| Operating Income | -$102.3M | -1.4% |
| Income Tax | $0 | — |
| Net Income | -$105.6M | -8.9% |
| EPS (Basic) | -$24.70 | -880.2% |
| EPS (Diluted) | -$24.70 | -880.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $69.3M | +43.0% |
| Short-term Investments | $19.1M | +571.7% |
| Current Assets | $89.5M | +63.1% |
| Total Assets | $92.2M | +56.8% |
| Current Liabilities | $47.5M | +261.7% |
| Total Liabilities | $64.4M | +361.8% |
| Stockholders' Equity | $27.8M | -38.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$45.7M | +52.9% |
| Capital Expenditures | $33K | +0.0% |
| Investing Cash Flow | -$15.9M | -129.0% |
| Financing Cash Flow | $82.5M | — |
| Free Cash Flow | -$45.8M | +52.9% |